Avdoralimab
As of the edition of 20 October 2026, Avdoralimab is an antibody: stopped in 2021; acts on C5AR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Antibody
- Registered trials
- 6, 1 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Cancer; Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Avdoralimab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | P21730 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 3 | 3 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Novo Nordisk | Lead sponsor of trials | 2012 to now |
| Innate Pharma | Lead sponsor of trials | 2018 to now |